logo
logo
LLY stock ticker logo

Eli Lilly and Company

NYSE•LLY
CEO: Mr. David A. Ricks
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 1972-06-01
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Contact Information
Lilly Corporate Center, Indianapolis, IN, 46285, United States
317-276-2000
www.lilly.com
Market Cap
$946.72B
P/E (TTM)
43.8
36.8
Dividend Yield
0.6%
52W High
$1.13K
52W Low
$623.78
52W Range
74%
Rank17Top 4.2%
6.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$19.29B+0.00%
4-Quarter Trend

EPS

$7.41+0.00%
4-Quarter Trend

FCF

$677.90M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Massive Revenue and Income Growth Revenue reached $65.18B, up 45%. Net income soared 95% to $20.64B, driven by strong volume and margin.
Cardiometabolic Blockbuster Performance Mounjaro revenue grew 99% to $22.97B total. Zepbound U.S. revenue surged 175% to $13.48B, showing high demand.
Gross Margin Expansion Noted Gross margin improved 1.7 percentage points to 83.0% in 2025, driven by favorable product mix and cost control.
Strong Liquidity Position Maintained Cash and equivalents totaled $7.27B at year-end 2025. Operating cash flow provided $16.81B for the year.

Risk Factors

Intellectual Property Expiry Risk Loss of exclusivity for key products like Trulicity faces generic competition, potentially causing rapid revenue declines.
Government Pricing Controls Impact IRA mandates government-set Medicare prices, accelerating revenue erosion for significant products like Jardiance and Trulicity.
Supply Chain and Manufacturing Risks Complex, highly regulated manufacturing processes face potential disruptions from external factors, increasing costs or causing shortages.
Cybersecurity and IT System Failure Failure or breach of IT systems, including third-party providers, risks material harm to business reputation and confidential data.

Outlook

Pipeline Advancement Key Focus Insulin efsitora alfa and Orforglipron submissions are under regulatory review, potentially expanding cardiometabolic portfolio value.
Manufacturing Capacity Expansion Significant capital expenditures are planned for global facilities expansion to meet existing and expected demand for medicines.
Navigating Global Pricing Uncertainty Management continues negotiating definitive agreements related to U.S. pricing deals and aligning strategies across developed nations.
Deploying Artificial Intelligence Exploring AI technologies in research, manufacturing, and commercialization presents opportunities but also entails regulatory risks.

Peer Comparison

Revenue (TTM)

JNJ stock ticker logoJNJ
$94.19B
+6.0%
LLY stock ticker logoLLY
$65.18B
+44.7%
MRK stock ticker logoMRK
$65.01B
+1.3%

Gross Margin (Latest Quarter)

MRK stock ticker logoMRK
92.7%
+2.2pp
GILD stock ticker logoGILD
86.8%
+0.7pp
JNJ stock ticker logoJNJ
86.4%
+18.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
LLY$946.72B43.897.9%37.8%
JNJ$591.15B22.433.8%24.1%
ABBV$417.62B98.5-361.6%51.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
14.9%
Steady Growth
4Q Net Income CAGR
34.0%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:Apr 29, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data